Sarah B Bateni1, Anders J Davidson1, Mili Arora2, Megan E Daly3, Susan L Stewart4, Richard J Bold1,5, Robert J Canter1,5, Candice A M Sauder6,7. 1. Department of Surgery, University of California, Davis Medical Center, Sacramento, CA, USA. 2. Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis Medical Center, Sacramento, CA, USA. 3. Department of Radiation Oncology, University of California, Davis Medical Center, Sacramento, CA, USA. 4. Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, Sacramento, CA, USA. 5. Division of Surgical Oncology, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA. 6. Department of Surgery, University of California, Davis Medical Center, Sacramento, CA, USA. camsauder@ucdavis.edu. 7. Division of Surgical Oncology, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA. camsauder@ucdavis.edu.
Abstract
BACKGROUND: Current treatment guidelines for male breast cancer are predominantly guided by female-only clinical trials. With scarce research, it is unclear whether breast-conserving therapy (BCT) is equivalent to mastectomy in men. We sought to compare overall survival (OS) among male breast cancer patients who underwent BCT versus mastectomy. METHODS: We performed a retrospective analysis of 8445 stage I-II (T1-2 N0-1 M0) male breast cancer patients from the National Cancer Database (2004-2014). Patients were grouped according to surgical and radiation therapy (RT). BCT was defined as partial mastectomy followed by RT. Multivariable and inverse probability of treatment-weighted (IPTW) Cox proportional hazards models were used to compare OS between treatment groups, controlling for demographic and clinicopathologic characteristics. RESULTS: Most patients underwent total mastectomy (61.2%), whereas 18.2% underwent BCT, 12.4% underwent total mastectomy with RT, and 8.2% underwent partial mastectomy alone. In multivariable and IPTW models, partial mastectomy alone, total mastectomy alone, and total mastectomy with RT were associated with worse OS compared with BCT (p < 0.001 all). Ten-year OS was 73.8% for BCT and 56.3, 58.0 and 56.3% for other treatment approaches. Older age, higher T/N stage, histological grade, and triple-negative receptor status were associated with poorer OS (p < 0.05). Subgroup analysis by stage demonstrated similar results. CONCLUSIONS: In this national sample of male breast cancer patients, BCT was associated with greater survival. The underlying mechanisms of this association warrant further study, because more routine adoption of BCT in male breast cancer appears to translate into clinically meaningful improvements in survival.
BACKGROUND: Current treatment guidelines for male breast cancer are predominantly guided by female-only clinical trials. With scarce research, it is unclear whether breast-conserving therapy (BCT) is equivalent to mastectomy in men. We sought to compare overall survival (OS) among male breast cancerpatients who underwent BCT versus mastectomy. METHODS: We performed a retrospective analysis of 8445 stage I-II (T1-2 N0-1 M0) male breast cancerpatients from the National Cancer Database (2004-2014). Patients were grouped according to surgical and radiation therapy (RT). BCT was defined as partial mastectomy followed by RT. Multivariable and inverse probability of treatment-weighted (IPTW) Cox proportional hazards models were used to compare OS between treatment groups, controlling for demographic and clinicopathologic characteristics. RESULTS: Most patients underwent total mastectomy (61.2%), whereas 18.2% underwent BCT, 12.4% underwent total mastectomy with RT, and 8.2% underwent partial mastectomy alone. In multivariable and IPTW models, partial mastectomy alone, total mastectomy alone, and total mastectomy with RT were associated with worse OS compared with BCT (p < 0.001 all). Ten-year OS was 73.8% for BCT and 56.3, 58.0 and 56.3% for other treatment approaches. Older age, higher T/N stage, histological grade, and triple-negative receptor status were associated with poorer OS (p < 0.05). Subgroup analysis by stage demonstrated similar results. CONCLUSIONS: In this national sample of male breast cancerpatients, BCT was associated with greater survival. The underlying mechanisms of this association warrant further study, because more routine adoption of BCT in male breast cancer appears to translate into clinically meaningful improvements in survival.
Authors: Bernard Fisher; Jong-Hyeon Jeong; Stewart Anderson; John Bryant; Edwin R Fisher; Norman Wolmark Journal: N Engl J Med Date: 2002-08-22 Impact factor: 91.245
Authors: Larissa A Korde; Jo Anne Zujewski; Leah Kamin; Sharon Giordano; Susan Domchek; William F Anderson; John M S Bartlett; Karen Gelmon; Zeina Nahleh; Jonas Bergh; Bruno Cutuli; Giancarlo Pruneri; Worta McCaskill-Stevens; Julie Gralow; Gabriel Hortobagyi; Fatima Cardoso Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: Min Yi; Funda Meric-Bernstam; Merrick I Ross; Jeri S Akins; Rosa F Hwang; Anthony Lucci; Henry M Kuerer; Gildy V Babiera; Michael Z Gilcrease; Kelly K Hunt Journal: Cancer Date: 2008-07-01 Impact factor: 6.860
Authors: Karl Y Bilimoria; David J Bentrem; Andrew K Stewart; David P Winchester; Clifford Y Ko Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544
Authors: Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark Journal: N Engl J Med Date: 2002-10-17 Impact factor: 91.245
Authors: Jennifer K Plichta; Yi Ren; Caitlin E Marks; Samantha M Thomas; Rachel A Greenup; Laura H Rosenberger; Oluwadamilola M Fayanju; Susan G R McDuff; E Shelley Hwang; Jeremy Force Journal: Ann Surg Oncol Date: 2020-07-23 Impact factor: 5.344
Authors: Sarah B Bateni; Lauren M Perry; Xiao Zhao; Mili Arora; Megan E Daly; Susan L Stewart; Richard J Bold; Robert J Canter; Candice A M Sauder Journal: Ann Surg Oncol Date: 2020-10-22 Impact factor: 5.344